Xvivo Perfusion AB (publ) reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was SEK 146.61 million compared to SEK 96.84 million a year ago. Net income was SEK 2.28 million compared to SEK 5.4 million a year ago. Basic earnings per share from continuing operations was SEK 0.08 compared to SEK 0.18 a year ago. Diluted earnings per share from continuing operations was SEK 0.08 compared to SEK 0.18 a year ago.
For the nine months, sales was SEK 441.8 million compared to SEK 283.78 million a year ago. Net income was SEK 23.35 million compared to SEK 17.69 million a year ago. Basic earnings per share from continuing operations was SEK 0.78 compared to SEK 0.6 a year ago. Diluted earnings per share from continuing operations was SEK 0.78 compared to SEK 0.6 a year ago.